Page 2 - Bharat Biotech

After Covishield, new study 'finds' side effects in Covaxin recipients

In observational study on Bharat Biotech's Covaxin recipients, about one-third of participants reported adverse events

Covaxin developed with focus on safety first, says Bharat Biotech

Bharat Biotech on Thursday asserted that its Covid-19 vaccine Covaxin is safe and devoid of any side-effects amid AstraZeneca's admission that Covishield could cause complications in rare cases. In a statement, the company stated that Covaxin was developed with a single-minded focus on safety first, followed by efficacy. The vaccine was evaluated in more than 27,000 subjects as part of its licensure process, Bharat Biotech stated. It was licensed under restricted use in clinical trial mode, where detailed safety reporting was carried out for several hundred thousand subjects, it noted. The vaccine was also evaluated by the Union Ministry of Health, it said. Besides, safety monitoring (pharmacovigilance) was continued throughout the product life cycle of Covaxin, it stated. All the above studies and safety follow-up activities have demonstrated an excellent safety record for Covaxin without any vaccine-associated incidents of blood clots, thrombocytopenia, TTS, VITT, pericarditis,

Bharat Biotech co-founder Krishna Ella takes helm as President of IVMA

Ella takes over the presidency from Adar C Poonawalla, who held the post from 2019 to March 2024

Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines

Bilthoven Biologicals will produce the vaccines for distribution in India and worldwide

Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines

Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Institute of India, to strengthen production and supply security of oral polio vaccines. An agreement has been signed between the two partners under which Bharat Biotech will procure drug substances for the production of oral polio vaccines (OPVs) to be supplied within India and globally, the company said in a statement. Through this collaboration, Bharat Biotech and Bilthoven Biologicals (BBio) will jointly obtain regulatory approvals and licences required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at BBio, it added. "This collaboration...exemplifies cooperation between vaccine companies, ensuring a secure supply of oral polio vaccines and fortifies the nation's mission to eradicate polio," Bharat Biotech Executive Chairman Krishna Ella said. Serum Institute of India CEO Adar ...

Bharat Biotech's TB vaccine MTBVAC begins clinical trials in India

The trials will assess the vaccine's safety, immune response, and efficacy in preventing TB in adults and adolescents. MTBVAC has been developed after research spanning over three decades

Shot stories: Meet Bharat Biotech's Krishna Ella, the man behind Covaxin

As the pandemic raged, India developed its own vaccine. Those weren't easy days, Ella, the man behind Covaxin, tells Sohini Das

Bharat Biotech, University of Sydney ink MoU for vaccine research

The international agreement aims to foster strong collaborations between sectors and organisations to develop innovative methods for tackling future epidemics and infectious diseases

TMS Ep529: Acquisition appetite, Krishna Ella, markets, sports associations

Why are business families in acquisition mode? How does Krishna Ella view Bharat Biotech's future? Is it time to bottom-fish in stock market? What happens when sports associations are suspended?

Bharat Biotech plans to invest Rs 3,000-4,000 crore in post-Covid shift

Not thinking about an IPO as of now, says chairman

We have one of the best TB vaccines in the world: Bharat Bio's Krishna Ella

'We are working on the TB vaccine as the Prime Minister's view is also to eradicate TB from the country'

Bharat Biotech picks up 20% stake in Eastman Exports Global Clothing

The Bharat Biotech Group has picked up 20 per cent in Tamil Nadu-based knitwear firm Eastman Exports Global Clothing Private Ltd, for an undisclosed amount. A press release from Eastman Exports said it will use the new investment for capital expenditure, strengthening backward integration and customer acquisition among others. The funds will also help the company expand its presence in the global apparel industry, especially at a time when other countries are facing a slowdown and to capture the overall China Plus One Strategy of divesting manufacturing away from a single country. Managing Director of Bharat Biotech, Suchitra Ella said, We are fully committed to the Make in India strategy across industries. India is one of the few vertically integrated countries in cotton-based apparels, our vision is to grow this industry and support manufacturing from India to the world. Our vision of supporting rural and semi-urban communities, especially women is addressed through this ...

300k doses of intranasal Covid vaccine sent to hospitals: Krishna Ella

Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday. He was speaking on the sidelines of an event here at which a bilateral agreement was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru. iNCOVACC, the world's first intranasal COVID-19 vaccine, was launched on January 26. The vaccine is now available on CoWIN and priced at Rs 800 for private markets and Rs 325 for the government of India and state governments. "We dispatched three lakh doses of the world's first intranasal COVID-19 vaccine to some hospitals two days ago," Ella said. On whether Bharat Biotech is looking at exporting the vaccine, he said some countries and international agencies are approaching the company for the intra-nasal vaccine. iNCOVACC is also the wor

iNCOVACC: All you need to know about world's first intranasal Covid vaccine

The vaccine been approved for use as a primary as well as a heterologous (mix-and-match) booster dose in India

Bharat Biotech rolls out India's first intra-nasal Covid vaccine iNCOVACC

Priced at Rs 800/dose for private players, Rs 325 for bulk procurement by govts

Health Minister Mandaviya launches Bharat Biotech's nasal Covid-19 vaccine

Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal Covid vaccine, iNCOVACC, on the occasion of Republic Day on Thursday. The world's first made-in-India intranasal vaccine was launched at Mandaviya's residence here. The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's (DCGI) approval in November for restricted emergency use among adults as a heterologous booster dose. According to a statement issued by Bharat Biotech earlier, 'iNCOVACC' is priced at Rs 800 for private markets and at Rs 325 for supplies to the government of India and state governments iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results, the Hyderabad-based vaccine maker had said. Clinical trials were conducted to evaluate iNCOVACC as a primary dose

Bharat Biotech starts voluntary recall of rabies vaccine after batch theft

Company had tested the batch and released it, but part of it was stolen, for which cold chain storage integrity was unknown. Decision made to recall the entire batch

First Indian intranasal Covid-19 vaccine to be launched on Jan 26

Homegrown vaccine maker Bharat Biotech will launch its intranasal Covid-19 vaccine iNCOVACC, the first of its kind in India, on Jan 26, the company's chairman and managing director Krishna Ella said

Ocugen announces positive data for Bharat Biotech's Covaxin in US trials

The study enrolled 419 US adult participants that were randomized 1:1 to receive two doses of Covaxin or placebo, 28 days apart

Ocugen-Bharat Biotech Covid vaccine meets main goals in US trial: Report

Ocugen Inc said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States